{"id":661,"date":"2013-03-19T11:08:44","date_gmt":"2013-03-19T10:08:44","guid":{"rendered":"http:\/\/www.gendiag.com\/thrombo-incode-en-el-foros-de-debat\/"},"modified":"2013-03-19T11:08:44","modified_gmt":"2013-03-19T10:08:44","slug":"thrombo-incode-en-el-foros-de-debat","status":"publish","type":"post","link":"https:\/\/www.gendiag.com\/ca\/thrombo-incode-en-el-foros-de-debat\/","title":{"rendered":"THROMBO INCODE EN EL FOROS DE DEBAT"},"content":{"rendered":"<p>Thrombo inCode s\u2019ha presentat a la Jornada\u00a0 organitzada per Asebio\u00a0 \u201cNoves Tecnologies basades en biomarcadors per hematologia\u201d<\/p>\n<p><em><\/em><!--more--><\/p>\n<p><strong>Madrid, 19 de mar\u00e7 de 2013 <\/strong><\/p>\n<p style=\"text-align: justify;\">S\u2019ha celebrat el Foro de Debat organitzat per Asebio (Associaci\u00f3 Espanyola de Bioempreses) com una oportunitat per a la col\u00b7laboraci\u00f3 entre el sector biotecnol\u00f2gic i el Sistema Nacional de Salut. En aquest entorn, el Dr. Eduardo Salas, director cient\u00edfic de Gendiag, ha presentat el seu desenvolupament Thrombo inCode, producte de diagn\u00f2stic que detecta els 12 factors de risc gen\u00e8tic associats a tromboembolisme i que millora la estrat\u00e8gia preventiva en pacients i familiars amb risc a patir esdeveniments tromboemb\u00f2lics.<\/p>\n<p style=\"text-align: justify;\">L\u2019acte va tenir lloc a la Fundaci\u00f3 Jim\u00e9nez D\u00edaz, de Madrid, amb una nodrida assist\u00e8ncia tant de personalitats de la Administraci\u00f3 com especialistes m\u00e8dics en aquest camp i empreses del sector.<\/p>\n<p style=\"text-align: justify;\"><a href=\"http:\/\/www.gendiag.com\/wp-content\/uploads\/2013\/02\/IMG_0473.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-434\" title=\"IMG_0473\" src=\"http:\/\/www.gendiag.com\/wp-content\/uploads\/2013\/02\/IMG_0473.jpg\" alt=\"\" width=\"1024\" height=\"768\" srcset=\"https:\/\/www.gendiag.com\/wp-content\/uploads\/2013\/02\/IMG_0473.jpg 1024w, https:\/\/www.gendiag.com\/wp-content\/uploads\/2013\/02\/IMG_0473-300x225.jpg 300w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Thrombo inCode s\u2019ha presentat a la Jornada\u00a0 organitzada per Asebio\u00a0 \u201cNoves Tecnologies basades en biomarcadors per hematologia\u201d<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-661","post","type-post","status-publish","format-standard","hentry","category-noticies"],"_links":{"self":[{"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/posts\/661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/comments?post=661"}],"version-history":[{"count":0,"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/posts\/661\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/media?parent=661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/categories?post=661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gendiag.com\/ca\/wp-json\/wp\/v2\/tags?post=661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}